Jodi L. Anderson

Spatial Transcriptomics Reveals Compartment-Specific Immune Activation Signatures in Ileal and Lymph Node Tissue in Treated HIV Infection

This study uses spatial transcriptomics to identify compartment-specific immune activation signatures in ileal and lymph node tissues of HIV-treated patients, revealing tissue-specific transcriptional differences linked to immune activation and microbial translocation.

Plasma metabolomics reveals lipid-predominant metabolic disruptions in virologically suppressed people with HIV

The paper uses metabolomics to show that HIV-treated individuals have metabolic disruptions, including lipid changes and inflammation markers, despite viral suppression.

Multi-omics links microbial dysbiosis, systemic inflammation and metabolomic disruptions to SNAE risk in treated HIV

This study links microbial dysbiosis, systemic inflammation, and metabolomic disruptions to SNAE risk in treated HIV patients through multi-omic analysis.

HIV-producing resting T cells monopolize virus production, associated PANoptosis, and persistence in lymphoid tissue

The paper identifies HIV-producing resting T cells as the primary source of virus production in lymphoid tissue germinal centers before ART and shows their role in PANoptosis and persistence during treatment.

HIV lymphoid tissue fibrosis occurs in the earliest stages of acute HIV infection and is associated with macrophage-derived TGF-β

The paper shows HIV causes collagen deposition in lymphoid tissue early in infection, linked to TGF-β+ macrophages and HIV RNA-producing cells, suggesting early ART may not prevent fibrosis.

Ongoing lymphoid HIV production drives pyroptosis and GLP-1 counter-regulation in ART-suppressed infection

The paper shows that residual HIV production in lymph nodes of ART-suppressed individuals drives pyroptosis and is counter-regulated by GLP-1 upregulation in the ileum.

Pre-treatment Microbiome Diversity and Function is associated with Expansion of Cytotoxic and Regulatory Immune Populations after N-803 treatment in People with HIV

This study shows that pre-treatment gut microbiome diversity in HIV patients correlates with immune activation and reduced HIV RNA+ cells after N-803 treatment.